PDF(Pubmed)
Abstract：
UNASSIGNED: Omalizumab has been approved for treating moderate-to-severe asthma in children aged over 6 years. Its application to asthmatic children with other allergic diseases has been rarely explored. The present study aims to explore the therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis.
UNASSIGNED: The clinical data of children diagnosed with moderate-to-severe allergic asthma combined with chronic sinusitis and treated with omalizumab between September 2020 and April 2022 were retrospectively analyzed. Lung function indexes such as Childhood Asthma Control Test (C-ACT) scores, fractional exhaled nitric oxide (FeNO), and forced expiratory volume in the first second (FEV1) percent predicted (FEV1%pred), small airway function indexes, and the clinical symptoms of chronic sinusitis were analyzed.
UNASSIGNED: A total of 26 children were observed for 16 weeks. After 16 weeks of omalizumab treatment, the significantly increased C-ACT scores (15.57 ± 3.25 points vs. 24.98 ± 5.21 points, F = 15.7112, P < 0.001) and decreased FeNO (31.55 ± 15.57 ppb vs. 19.86 ± 9.80 ppb, F = 4.4265, P = 0.0022), compared with those at baseline, were suggestive of well-controlled symptoms of asthma and improved lung function. FEV1%pred and FEV1/forced vital capacity (FVC) ratio (the ratio of the forced expiratory volume in the first 1 s to the forced vital capacity) increased after omalizumab treatment, although no significant differences were detected (P = 0.9954 and 0.9382, respectively). Peak expiratory flow (PEF) percent predicted (PEF%pred) and forced expiratory flow at 75% of FVC (FEF75%), 50% of FVC (FEF50%), and 25%-75% of FVC (FEF25%-75%) significantly increased after omalizumab treatment (P = 0.0477, <0.001, <0.001, and <0.001, respectively). Visual analog scale scores significantly decreased after omalizumab treatment (6.40 ± 2.98 points vs. 0.85 ± 0.40 points, t = 27.2419, P < 0.001), suggesting alleviation in the clinical symptoms of chronic sinusitis.
UNASSIGNED: In this study, it was found that omalizumab can effectively alleviate clinical symptoms and improve lung function and quality of life in children with moderate-to-severe allergic asthma combined with chronic sinusitis.
UNASSIGNED: The clinical data of children diagnosed with moderate-to-severe allergic asthma combined with chronic sinusitis and treated with omalizumab between September 2020 and April 2022 were retrospectively analyzed. Lung function indexes such as Childhood Asthma Control Test (C-ACT) scores, fractional exhaled nitric oxide (FeNO), and forced expiratory volume in the first second (FEV1) percent predicted (FEV1%pred), small airway function indexes, and the clinical symptoms of chronic sinusitis were analyzed.
UNASSIGNED: A total of 26 children were observed for 16 weeks. After 16 weeks of omalizumab treatment, the significantly increased C-ACT scores (15.57 ± 3.25 points vs. 24.98 ± 5.21 points, F = 15.7112, P < 0.001) and decreased FeNO (31.55 ± 15.57 ppb vs. 19.86 ± 9.80 ppb, F = 4.4265, P = 0.0022), compared with those at baseline, were suggestive of well-controlled symptoms of asthma and improved lung function. FEV1%pred and FEV1/forced vital capacity (FVC) ratio (the ratio of the forced expiratory volume in the first 1 s to the forced vital capacity) increased after omalizumab treatment, although no significant differences were detected (P = 0.9954 and 0.9382, respectively). Peak expiratory flow (PEF) percent predicted (PEF%pred) and forced expiratory flow at 75% of FVC (FEF75%), 50% of FVC (FEF50%), and 25%-75% of FVC (FEF25%-75%) significantly increased after omalizumab treatment (P = 0.0477, <0.001, <0.001, and <0.001, respectively). Visual analog scale scores significantly decreased after omalizumab treatment (6.40 ± 2.98 points vs. 0.85 ± 0.40 points, t = 27.2419, P < 0.001), suggesting alleviation in the clinical symptoms of chronic sinusitis.
UNASSIGNED: In this study, it was found that omalizumab can effectively alleviate clinical symptoms and improve lung function and quality of life in children with moderate-to-severe allergic asthma combined with chronic sinusitis.
摘要：
■奥马珠单抗已被批准用于治疗6岁以上儿童的中度至重度哮喘。很少探索其在患有其他过敏性疾病的哮喘儿童中的应用。本研究旨在探讨奥马珠单抗对儿童中重度过敏性哮喘合并慢性鼻窦炎的治疗效果。
■回顾性分析2020年9月至2022年4月期间诊断为中度至重度过敏性哮喘合并慢性鼻窦炎并接受奥马珠单抗治疗的儿童的临床资料。肺功能指标，如儿童哮喘控制测试（C-ACT）评分，呼出气一氧化氮（FeNO），和第一秒用力呼气量(FEV1)预测百分比(FEV1%pred)，小气道功能指标，并对慢性鼻窦炎的临床症状进行分析。
■共观察了26名儿童16周。奥马珠单抗治疗16周后，C-ACT得分显着增加（15.57±3.25分vs.24.98±5.21分,F=15.7112，P<0.001）和降低的FeNO（31.55±15.57ppbvs.19.86±9.80ppb，F=4.4265,P=0.0022),与基线相比，提示哮喘症状控制良好，肺功能改善。在奥马珠单抗治疗后，FEV1％pred和FEV1/用力肺活量（FVC）比率（前1s用力呼气量与用力肺活量的比率）增加，尽管没有检测到显着差异（分别为P=0.9954和0.9382）。峰值呼气流量(PEF)预测百分比(PEF%pred)和75%FVC时的强制呼气流量(FEF75%),FVC的50%(FEF50%),25％-75％的FVC（FEF25％-75％）在奥马珠单抗治疗后显着增加（分别为P=0.0477，<0.001，<0.001和<0.001）。奥马珠单抗治疗后视觉模拟评分明显下降（6.40±2.98分vs.0.85±0.40分,t=27.2419,P<0.001),提示缓解慢性鼻窦炎的临床症状。
■在这项研究中，研究发现，奥马珠单抗可有效缓解中重度过敏性哮喘合并慢性鼻窦炎患儿的临床症状，改善肺功能和生活质量。
■回顾性分析2020年9月至2022年4月期间诊断为中度至重度过敏性哮喘合并慢性鼻窦炎并接受奥马珠单抗治疗的儿童的临床资料。肺功能指标，如儿童哮喘控制测试（C-ACT）评分，呼出气一氧化氮（FeNO），和第一秒用力呼气量(FEV1)预测百分比(FEV1%pred)，小气道功能指标，并对慢性鼻窦炎的临床症状进行分析。
■共观察了26名儿童16周。奥马珠单抗治疗16周后，C-ACT得分显着增加（15.57±3.25分vs.24.98±5.21分,F=15.7112，P<0.001）和降低的FeNO（31.55±15.57ppbvs.19.86±9.80ppb，F=4.4265,P=0.0022),与基线相比，提示哮喘症状控制良好，肺功能改善。在奥马珠单抗治疗后，FEV1％pred和FEV1/用力肺活量（FVC）比率（前1s用力呼气量与用力肺活量的比率）增加，尽管没有检测到显着差异（分别为P=0.9954和0.9382）。峰值呼气流量(PEF)预测百分比(PEF%pred)和75%FVC时的强制呼气流量(FEF75%),FVC的50%(FEF50%),25％-75％的FVC（FEF25％-75％）在奥马珠单抗治疗后显着增加（分别为P=0.0477，<0.001，<0.001和<0.001）。奥马珠单抗治疗后视觉模拟评分明显下降（6.40±2.98分vs.0.85±0.40分,t=27.2419,P<0.001),提示缓解慢性鼻窦炎的临床症状。
■在这项研究中，研究发现，奥马珠单抗可有效缓解中重度过敏性哮喘合并慢性鼻窦炎患儿的临床症状，改善肺功能和生活质量。
